DE69710896D1 - Progestogen-anti-progestogen therapien - Google Patents

Progestogen-anti-progestogen therapien

Info

Publication number
DE69710896D1
DE69710896D1 DE69710896T DE69710896T DE69710896D1 DE 69710896 D1 DE69710896 D1 DE 69710896D1 DE 69710896 T DE69710896 T DE 69710896T DE 69710896 T DE69710896 T DE 69710896T DE 69710896 D1 DE69710896 D1 DE 69710896D1
Authority
DE
Germany
Prior art keywords
progestogen
therapien
hrt
estrogen
cycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69710896T
Other languages
German (de)
Other versions
DE69710896T2 (en
Inventor
Bennink Herman Jan Ti Coelingh
Pieter M Verbost
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Publication of DE69710896D1 publication Critical patent/DE69710896D1/en
Application granted granted Critical
Publication of DE69710896T2 publication Critical patent/DE69710896T2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Glass Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Disclosed is a contraceptive and/or HRT (hormone replacement therapy) kit comprising sequential daily dosage units each containing as the sole contraceptively effective ingredient of a progestogen, or as effective ingredient for HRT a progestogen with or without an estrogen or an estrogen only, and further two or more dosage units comprising an anti-progestogen. One of the anti-progestogen is administered at the beginning and the others regularly divided throughout the cycle, preferably one only in the middle of the cycle.
DE69710896T 1996-06-25 1997-06-23 PROGESTOGEN-ANTI-PROGESTOGEN THERAPIES Expired - Fee Related DE69710896T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201744 1996-06-25
PCT/EP1997/003288 WO1997049407A1 (en) 1996-06-25 1997-06-23 Progestogen-anti-progestogen regimens

Publications (2)

Publication Number Publication Date
DE69710896D1 true DE69710896D1 (en) 2002-04-11
DE69710896T2 DE69710896T2 (en) 2002-09-26

Family

ID=8224104

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69710896T Expired - Fee Related DE69710896T2 (en) 1996-06-25 1997-06-23 PROGESTOGEN-ANTI-PROGESTOGEN THERAPIES

Country Status (17)

Country Link
EP (1) EP0912186B1 (en)
JP (1) JP2000514785A (en)
KR (1) KR20000022189A (en)
AT (1) ATE213947T1 (en)
AU (1) AU725670B2 (en)
BR (1) BR9709934A (en)
CA (1) CA2255863A1 (en)
CZ (1) CZ290697B6 (en)
DE (1) DE69710896T2 (en)
ES (1) ES2174265T3 (en)
HK (1) HK1019305A1 (en)
NO (1) NO986104L (en)
NZ (1) NZ332894A (en)
PL (1) PL330916A1 (en)
RU (1) RU2189819C2 (en)
TR (1) TR199802705T2 (en)
WO (1) WO1997049407A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0100542A3 (en) 1997-11-14 2001-10-29 Akzo Nobel Nv Progestogen and antiprogestogen containing kit, process for its preparation and use of the compounds for the preparation of contraseptives
ATE277618T1 (en) * 1999-04-29 2004-10-15 Akzo Nobel Nv USE OF ORG 33245 IN COMBINED INTERMITTENT HORMONE THERAPY AND CONTRACEPTION
US6498154B1 (en) * 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6380178B1 (en) * 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
WO2000066168A1 (en) * 1999-05-04 2000-11-09 American Home Products Corporation Compositions containing benzimidazolones and progestogens
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
DE60013798T2 (en) * 1999-05-04 2005-09-29 Wyeth RECIPROCAL COMPOSITIONS CONTAINING THE PROGESTAGES AND PROGESTERONANT AGONISTS
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6329416B1 (en) * 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6462032B1 (en) * 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6399593B1 (en) * 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
CA2383650A1 (en) * 1999-08-31 2001-04-19 Jenapharm Gmbh & Co. Kg Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
HUP0202460A3 (en) * 1999-08-31 2004-04-28 Schering Ag Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt)
US7629334B1 (en) 1999-08-31 2009-12-08 Bayer Schering Pharma Aktiengesellschaft Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
US7772219B2 (en) * 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
TW200531977A (en) 2004-03-25 2005-10-01 Akzo Nobel Nv Progesterone receptor modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1918092A (en) * 1992-05-06 1993-11-29 Medical College Of Hampton Roads, The Minimizing progestin associated breakthrough bleeding
ZA935617B (en) * 1992-08-14 1994-03-07 Akzo Nv Antiprogestogen containing contraceptives.
DE4344463A1 (en) * 1993-12-22 1995-06-29 Schering Ag Combination product for contraception
DK0792152T3 (en) * 1994-11-22 2004-07-12 Balance Pharmaceuticals Inc Procedures for Pregnancy Prevention

Also Published As

Publication number Publication date
KR20000022189A (en) 2000-04-25
HK1019305A1 (en) 2000-02-03
RU2189819C2 (en) 2002-09-27
BR9709934A (en) 1999-08-10
JP2000514785A (en) 2000-11-07
PL330916A1 (en) 1999-06-07
CA2255863A1 (en) 1997-12-31
TR199802705T2 (en) 1999-03-22
AU725670B2 (en) 2000-10-19
NO986104D0 (en) 1998-12-23
NO986104L (en) 1998-12-23
AU3436097A (en) 1998-01-14
EP0912186A1 (en) 1999-05-06
WO1997049407A1 (en) 1997-12-31
CZ428998A3 (en) 1999-08-11
ES2174265T3 (en) 2002-11-01
ATE213947T1 (en) 2002-03-15
DE69710896T2 (en) 2002-09-26
CZ290697B6 (en) 2002-09-11
NZ332894A (en) 1999-05-28
EP0912186B1 (en) 2002-03-06

Similar Documents

Publication Publication Date Title
DE69710896D1 (en) Progestogen-anti-progestogen therapien
UA48973C2 (en) Transdermal patch containing 17-deacetyl norgestimate for preventing ovulation
ZA897977B (en) Contraception system and method
MX9804395A (en) Contraceptive process and kit for female mammals, comprising a combination of gestagen and oestrogen.
AU645382B2 (en) Low estrogen oral contraceptives
ATE239483T1 (en) PHARMACEUTICAL COMBINATION PREPARATION, KIT AND METHOD FOR HORMONAL CONTRACEPTION
BG101553A (en) Progesterone antagonist and antiestrogenous active compounds of general application for female contraceptives
NZ333750A (en) Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
BG101427A (en) Competitive progesterone antagonists for regulating female fertility as required
NZ504351A (en) Contraceptive kit comprising progestogen and anti-progestogen and use in treating bleeding induced by a progestogen-only contraceptive regimen
HUP9903097A2 (en) Medicament containing progestogen-anti-progestogen
MX9707009A (en) Once-a-month-injectable useful as depot contraceptive and in hormone replacement therapy for perimenopausal and premenopausal women.

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee